Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: therapeutic autologous lymphocytes
Procedure: in vitro-treated peripheral blood stem cell transplantation
Biological: gp100 antigen
Biological: MART-1 antigen
Biological: incomplete Freund's adjuvant
Biological: filgrastim
Biological: aldesleukin

First Posted Date: 2006-03-17

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00303836

Locations: 🇺🇸
National Cancer Institute Surgery Branch, Bethesda, Maryland, United States

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: pegfilgrastim
Drug: capecitabine
Drug: cyclophosphamide
Drug: epirubicin hydrochloride
Procedure: adjuvant therapy
Drug: fluorouracil
Drug: methotrexate

First Posted Date: 2006-03-13

Last Posted Date: 2018-08-08

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 4400

Registration Number: NCT00301925

Locations: 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
🇬🇧
Burnley General Hospital, Burnley, England, United Kingdom

and more 147 locations

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Childhood Favorable Prognosis Hodgkin Lymphoma
Childhood Lymphocyte Depletion Hodgkin Lymphoma
Childhood Mixed Cellularity Hodgkin Lymphoma
Childhood Nodular Sclerosis Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma

Interventions: Radiation: radiation therapy
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: cyclophosphamide
Drug: ifosfamide
Drug: vinorelbine tartrate
Drug: dexamethasone
Drug: etoposide phosphate
Drug: cisplatin
Drug: cytarabine
Biological: filgrastim

First Posted Date: 2006-03-13

Last Posted Date: 2021-03-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 287

Registration Number: NCT00302003

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: epratuzumab
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2006-03-13

Last Posted Date: 2019-10-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 107

Registration Number: NCT00301821

Locations: 🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸
Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States

and more 156 locations

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: AMG 531
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Methotrexate
Drug: Placebo
Drug: Cytarabine

First Posted Date: 2006-03-06

Last Posted Date: 2021-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00299182

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II High-Dose Cyclophosphamide for Multiple Sclerosis

Phase 2

Withdrawn

Conditions: Multiple Sclerosis

First Posted Date: 2006-02-24

Last Posted Date: 2009-07-22

Lead Sponsor: Stony Brook University

Target Recruit Count: 25

Registration Number: NCT00296205

Locations: 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: methotrexate
Radiation: radiation therapy
Procedure: adjuvant therapy

First Posted Date: 2006-02-24

Last Posted Date: 2021-02-23

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 77

Registration Number: NCT00296010

Locations: 🇧🇪
Centre Hospitalier Etterbeek Ixelles, Brussels, Belgium
🇧🇪
AZ Groeninge - Oncologisch Centrum, Kortrijk, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium

and more 30 locations

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Not Applicable

Conditions: Chronic Myeloproliferative Disorders
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2006-02-24

Last Posted Date: 2014-01-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00295997

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: prednisone

First Posted Date: 2006-02-24

Last Posted Date: 2018-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT00295932

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: docetaxel
Biological: Trastuzumab
Drug: doxorubicin hydrochloride
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-24

Last Posted Date: 2025-01-10

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 121

Registration Number: NCT00295893

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy